Galectin Historical Balance Sheet

GALT Stock

USD 1.55 0.08 5.44%

Trend analysis of Galectin Therapeutics balance sheet accounts such as Other Current Liabilities of 11.1 M or Total Current Liabilities of 18.9 M provides information on Galectin Therapeutics' total assets, liabilities, and equity, which is the actual value of Galectin Therapeutics to its prevalent stockholders. By breaking down trends over time using Galectin Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Galectin Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Galectin Therapeutics is a good buy for the upcoming year.

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galectin Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Galectin Stock please use our How to Invest in Galectin Therapeutics guide.

About Galectin Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Galectin Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Galectin Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Galectin Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Galectin currently owns. An asset can also be divided into two categories, current and non-current.

Galectin Therapeutics Balance Sheet Chart

At this time, Galectin Therapeutics' Non Currrent Assets Other are comparatively stable compared to the past year. Cash And Short Term Investments is likely to gain to about 31 M in 2025, whereas Common Stock Total Equity is likely to drop slightly above 35.5 K in 2025.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities Accounts Payable Accumulated Other Comprehensive Income

Add Fundamental

Total Assets

Total assets refers to the total amount of Galectin Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Galectin Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Galectin Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Galectin Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Accounts Payable

An accounting item on the balance sheet that represents Galectin Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Galectin Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Accumulated Other Comprehensive Income

Gains and losses not included in net income that are recorded in shareholders' equity, reflecting changes in the value of assets or liabilities that are not realized.

Most accounts from Galectin Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Galectin Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galectin Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Galectin Stock please use our How to Invest in Galectin Therapeutics guide.At this time, Galectin Therapeutics' Non Currrent Assets Other are comparatively stable compared to the past year. Cash And Short Term Investments is likely to gain to about 31 M in 2025, whereas Common Stock Total Equity is likely to drop slightly above 35.5 K in 2025.

	2022	2023	2024	2025 (projected)
Short and Long Term Debt Total	39.9M	71.8M	82.6M	86.7M
Total Assets	21.3M	28.2M	32.4M	34.1M

Short Long Term Debt Total Total Assets

Galectin Therapeutics balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Property Plant And Equipment Net	Other Assets	Other Current Assets	Property Plant And Equipment Gross	Property Plant Equipment	Current Deferred Revenue	Non Current Liabilities Total
Total Assets		0.43	0.46	0.47	-0.03	-0.03	-0.64	0.48	1.0	0.25	0.25	1.0	0.68	0.71	0.74	0.44	1.0	-0.49	0.68	-0.04	0.1	0.6	0.04	-0.1	-0.51	0.4
Short Long Term Debt Total	0.43		0.94	0.98	-0.9	0.88	-0.77	0.98	0.38	0.78	0.74	0.38	0.53	0.75	0.75	1.0	0.42	-0.1	0.59	-0.08	0.06	0.47	-0.03	-0.3	-0.28	0.99
Other Current Liab	0.46	0.94		0.99	-0.84	0.82	-0.87	0.92	0.4	0.8	0.78	0.4	0.67	0.85	0.84	0.95	0.45	-0.26	0.72	0.08	0.32	0.65	0.15	-0.36	-0.36	0.92
Total Current Liabilities	0.47	0.98	0.99		-0.86	0.84	-0.86	0.97	0.42	0.82	0.79	0.42	0.64	0.84	0.83	0.98	0.46	-0.18	0.69	0.03	0.18	0.58	0.09	-0.33	-0.35	0.96
Total Stockholder Equity	-0.03	-0.9	-0.84	-0.86		-0.99	0.59	-0.85	0.03	-0.76	-0.71	0.03	-0.3	-0.51	-0.49	-0.9	-0.01	-0.07	-0.37	0.03	-0.11	-0.25	0.02	0.33	0.06	-0.91
Net Debt	-0.03	0.88	0.82	0.84	-0.99		-0.55	0.83	-0.09	0.75	0.7	-0.09	0.27	0.49	0.46	0.88	-0.05	0.13	0.34	-0.04	0.07	0.24	-0.02	-0.28	-0.05	0.89
Retained Earnings	-0.64	-0.77	-0.87	-0.86	0.59	-0.55		-0.8	-0.6	-0.75	-0.76	-0.6	-0.9	-0.97	-0.97	-0.78	-0.63	0.41	-0.92	-0.23	-0.35	-0.7	-0.33	0.26	0.6	-0.73
Accounts Payable	0.48	0.98	0.92	0.97	-0.85	0.83	-0.8		0.44	0.82	0.78	0.44	0.57	0.79	0.79	0.98	0.47	-0.06	0.62	-0.04	-0.02	0.45	0.01	-0.28	-0.33	0.97
Cash	1.0	0.38	0.4	0.42	0.03	-0.09	-0.6	0.44		0.2	0.2	1.0	0.65	0.66	0.7	0.39	1.0	-0.49	0.65	-0.06	0.08	0.56	0.02	-0.08	-0.49	0.35
Non Current Assets Total	0.25	0.78	0.8	0.82	-0.76	0.75	-0.75	0.82	0.2		1.0	0.2	0.59	0.73	0.71	0.78	0.23	0.03	0.62	0.39	0.25	0.3	0.45	-0.16	-0.27	0.76
Non Currrent Assets Other	0.25	0.74	0.78	0.79	-0.71	0.7	-0.76	0.78	0.2	1.0		0.2	0.61	0.74	0.71	0.74	0.24	0.02	0.64	0.46	0.3	0.31	0.52	-0.13	-0.28	0.72
Cash And Short Term Investments	1.0	0.38	0.4	0.42	0.03	-0.09	-0.6	0.44	1.0	0.2	0.2		0.65	0.66	0.7	0.39	1.0	-0.49	0.65	-0.06	0.08	0.56	0.02	-0.08	-0.49	0.35
Common Stock Total Equity	0.68	0.53	0.67	0.64	-0.3	0.27	-0.9	0.57	0.65	0.59	0.61	0.65		0.9	0.88	0.53	0.68	-0.38	1.0	0.29	0.4	0.72	0.4	-0.01	-0.55	0.47
Common Stock Shares Outstanding	0.71	0.75	0.85	0.84	-0.51	0.49	-0.97	0.79	0.66	0.73	0.74	0.66	0.9		0.99	0.76	0.7	-0.4	0.92	0.17	0.33	0.76	0.3	-0.14	-0.57	0.71
Other Stockholder Equity	0.74	0.75	0.84	0.83	-0.49	0.46	-0.97	0.79	0.7	0.71	0.71	0.7	0.88	0.99		0.76	0.73	-0.43	0.9	0.18	0.26	0.72	0.29	-0.21	-0.63	0.7
Total Liab	0.44	1.0	0.95	0.98	-0.9	0.88	-0.78	0.98	0.39	0.78	0.74	0.39	0.53	0.76	0.76		0.43	-0.13	0.6	-0.08	0.09	0.49	-0.02	-0.32	-0.27	0.99
Total Current Assets	1.0	0.42	0.45	0.46	-0.01	-0.05	-0.63	0.47	1.0	0.23	0.24	1.0	0.68	0.7	0.73	0.43		-0.49	0.68	-0.05	0.1	0.59	0.03	-0.09	-0.5	0.39
Short Term Debt	-0.49	-0.1	-0.26	-0.18	-0.07	0.13	0.41	-0.06	-0.49	0.03	0.02	-0.49	-0.38	-0.4	-0.43	-0.13	-0.49		-0.37	0.05	-0.47	-0.41	-0.01	0.55	0.48	-0.08
Common Stock	0.68	0.59	0.72	0.69	-0.37	0.34	-0.92	0.62	0.65	0.62	0.64	0.65	1.0	0.92	0.9	0.6	0.68	-0.37		0.27	0.4	0.73	0.37	-0.04	-0.54	0.54
Property Plant And Equipment Net	-0.04	-0.08	0.08	0.03	0.03	-0.04	-0.23	-0.04	-0.06	0.39	0.46	-0.06	0.29	0.17	0.18	-0.08	-0.05	0.05	0.27		0.46	-0.05	0.97	-0.01	-0.2	-0.11
Other Assets	0.1	0.06	0.32	0.18	-0.11	0.07	-0.35	-0.02	0.08	0.25	0.3	0.08	0.4	0.33	0.26	0.09	0.1	-0.47	0.4	0.46		0.47	0.52	-0.13	-0.12	0.06
Other Current Assets	0.6	0.47	0.65	0.58	-0.25	0.24	-0.7	0.45	0.56	0.3	0.31	0.56	0.72	0.76	0.72	0.49	0.59	-0.41	0.73	-0.05	0.47		0.06	-0.11	-0.35	0.42
Property Plant And Equipment Gross	0.04	-0.03	0.15	0.09	0.02	-0.02	-0.33	0.01	0.02	0.45	0.52	0.02	0.4	0.3	0.29	-0.02	0.03	-0.01	0.37	0.97	0.52	0.06		0.1	-0.26	-0.06
Property Plant Equipment	-0.1	-0.3	-0.36	-0.33	0.33	-0.28	0.26	-0.28	-0.08	-0.16	-0.13	-0.08	-0.01	-0.14	-0.21	-0.32	-0.09	0.55	-0.04	-0.01	-0.13	-0.11	0.1		0.32	-0.31
Current Deferred Revenue	-0.51	-0.28	-0.36	-0.35	0.06	-0.05	0.6	-0.33	-0.49	-0.27	-0.28	-0.49	-0.55	-0.57	-0.63	-0.27	-0.5	0.48	-0.54	-0.2	-0.12	-0.35	-0.26	0.32		-0.22
Non Current Liabilities Total	0.4	0.99	0.92	0.96	-0.91	0.89	-0.73	0.97	0.35	0.76	0.72	0.35	0.47	0.71	0.7	0.99	0.39	-0.08	0.54	-0.11	0.06	0.42	-0.06	-0.31	-0.22

Click cells to compare fundamentals

Galectin Therapeutics Account Relationship Matchups

Galectin Therapeutics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	29.6M	41.8M	21.3M	28.2M	32.4M	34.1M
Short Long Term Debt Total	44K	29.1M	39.9M	71.8M	82.6M	86.7M
Other Current Liab	4.1M	7.2M	9.1M	9.2M	10.6M	11.1M
Total Current Liabilities	5.4M	9.0M	13.0M	15.7M	18.0M	18.9M
Total Stockholder Equity	29.6M	893K	(33.9M)	(60.2M)	(54.2M)	(51.5M)
Net Debt	(27.1M)	(10.6M)	21.3M	46.1M	41.5M	43.6M
Retained Earnings	(240.0M)	(270.7M)	(309.6M)	(354.4M)	(318.9M)	(303.0M)
Accounts Payable	1.3M	1.8M	3.9M	6.4M	7.4M	7.8M
Cash	27.1M	39.6M	18.6M	25.7M	29.5M	31.0M
Non Current Assets Total	135K	7K	733K	490K	563.5K	591.7K
Non Currrent Assets Other	135K	7K	733K	437K	502.6K	527.7K
Cash And Short Term Investments	27.1M	39.6M	18.6M	25.7M	29.5M	31.0M
Common Stock Shares Outstanding	57.0M	58.5M	59.4M	60.2M	69.2M	72.6M
Liabilities And Stockholders Equity	29.6M	41.8M	21.3M	28.2M	32.4M	34.1M
Other Stockholder Equity	261.9M	271.0M	275.1M	291.8M	335.6M	352.4M
Total Liab	5.4M	40.9M	55.2M	88.4M	101.7M	106.8M
Total Current Assets	29.5M	41.8M	20.6M	27.7M	31.9M	33.5M
Short Term Debt	44K	8K	40K	46K	41.4K	39.3K
Property Plant And Equipment Net	135K	7K	733K	53K	61.0K	57.9K
Other Current Assets	4.6M	4.3M	2.0M	2.1M	2.4M	2.5M
Property Plant And Equipment Gross	209K	81K	807K	74K	85.1K	137.0K
Non Current Liabilities Total	(5.4M)	31.9M	42.2M	72.8M	83.7M	87.9M
Net Tangible Assets	45.1M	21.9M	366K	(34.4M)	(31.0M)	(29.4M)
Net Invested Capital	21.9M	29.4M	5.4M	9.3M	10.7M	15.6M
Net Working Capital	24.1M	32.8M	7.5M	12.0M	13.8M	20.3M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Galectin Stock Analysis

When running Galectin Therapeutics' price analysis, check to measure Galectin Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galectin Therapeutics is operating at the current time. Most of Galectin Therapeutics' value examination focuses on studying past and present price action to predict the probability of Galectin Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galectin Therapeutics' price. Additionally, you may evaluate how the addition of Galectin Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Galectin Historical Balance Sheet

About Galectin Balance Sheet Analysis

Galectin Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Accounts Payable

Accumulated Other Comprehensive Income

Galectin Therapeutics balance sheet Correlations

Galectin Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Galectin Therapeutics balance sheet Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Galectin Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Liab	+ 1.0	Short Long Term Debt Total
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash

Net Debt	- 0.99	Total Stockholder Equity
Other Stockholder Equity	- 0.97	Retained Earnings
Common Stock Shares Outstanding	- 0.97	Retained Earnings
Common Stock	- 0.92	Retained Earnings
Non Current Liabilities Total	- 0.91	Total Stockholder Equity
Common Stock Total Equity	- 0.9	Retained Earnings